Skip to main content

Table 1 Drug repositioning candidates for Melanoma. Drugs showing a negative correlation score less than or equal to − 0.40 and affecting more than 50% of the dysregulated pathways in melanoma. The last column outlines the current uses of the given drug in other conditions according to DrugBank and scientific literature

From: PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures

Drug

DrugBank ID

Correlation Score

Affected Pathways (%)

Description

Crizotinib

DB08865

−0.64

74.07

Used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).

Olmesartan

DB00275

−0.85

55.56

Used for the treatment of hypertension.

Sepantronium

–

−0.21

74.07

Clinical trials in advanced non-small-cell lung cancer.

Bortezomib

DB00188

−0.52

62.96

Used for the treatment of multiple myeloma.

Fluspirilene

DB04842

−0.5

55.56

Used for the treatment of schizophrenia.

Vistusertib

DB11925

−0.44

66.67

Under investigation for the treatment of Advanced Gastric Adenocarcinoma.

Olaparib

DB09074

−0.44

66.67

A poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of Ovarian and Breast Cancer.

Tivozanib

DB11800

−0.44

66.67

Used in trials for the treatment of solid tumors, Ovarian Cancer, Glioblastoma, Prostate Cancer among others.

Belinostat

DB05015

−0.43

55.56

Used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).